- Home
- GANX vs CCEL Comparison
GANX vs CCEL Comparison
Compare GANX & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GANX
- CCEL
- Stock Information
- Founded
- GANX 2017
- CCEL 1989
- Country
- GANX United States
- CCEL United States
- Employees
- GANX N/A
- CCEL N/A
- Industry
- GANX Biotechnology: Pharmaceutical Preparations
- CCEL Managed Health Care
- Sector
- GANX Health Care
- CCEL Health Care
- Exchange
- GANX Nasdaq
- CCEL Nasdaq
- Market Cap
- GANX 41.9M
- CCEL 50.0M
- IPO Year
- GANX 2021
- CCEL 1997
- Fundamental
- Price
- GANX $1.58
- CCEL $7.78
- Analyst Decision
- GANX Strong Buy
- CCEL
- Analyst Count
- GANX 5
- CCEL 0
- Target Price
- GANX $7.60
- CCEL N/A
- AVG Volume (30 Days)
- GANX 204.1K
- CCEL 12.9K
- Earning Date
- GANX 11-14-2024
- CCEL 12-31-2024
- Dividend Yield
- GANX N/A
- CCEL 3.13%
- EPS Growth
- GANX N/A
- CCEL N/A
- EPS
- GANX N/A
- CCEL N/A
- Revenue
- GANX N/A
- CCEL $31,838,476.00
- Revenue This Year
- GANX N/A
- CCEL $3.97
- Revenue Next Year
- GANX N/A
- CCEL $0.91
- P/E Ratio
- GANX N/A
- CCEL N/A
- Revenue Growth
- GANX N/A
- CCEL 1.95
- 52 Week Low
- GANX $0.89
- CCEL $4.47
- 52 Week High
- GANX $5.33
- CCEL $9.50
- Technical
- Relative Strength Index (RSI)
- GANX 42.64
- CCEL 45.13
- Support Level
- GANX $1.59
- CCEL $7.60
- Resistance Level
- GANX $1.70
- CCEL $9.10
- Average True Range (ATR)
- GANX 0.15
- CCEL 0.27
- MACD
- GANX 0.00
- CCEL -0.15
- Stochastic Oscillator
- GANX 19.74
- CCEL 23.61
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment.